Heat Biologics

Heat Biologics Inc. is a US biotechnology company focused on the field of immunotherapy. Heat Biologics was founded by serial bio-tech entrepreneur Jeff Wolf and scientific cofounder Eckhard Podack, based upon Dr. Podack's novel work in the development of gp96 and other approaches to modulate the immune system, with multiple programs for indications in cancer, COVID-19, infectious disease, and others. The company is based in Morrisville, North Carolina.
"gp96".
Heat Biologics’ proprietary gp96 platform leverages gp96’s role as a natural molecular warning system, engineered to secrete antigens bound to gp96, with broad applications in cancer treatment and vaccines for infectious diseases. Their lead product is in a Phase 2 trial for treatment of non-small cell lung cancer (NSCLC).
Pipeline products.
HS-110.
HS-110, also called viagenpumatucel-L, is in Phase II in NSCLC, in combination with cyclophosphamide. Another Phase I study is combining HS 110 with nivolumab and other checkpoint inhibitors.
HS-130.
HS-130 is in Phase I clinical trial for patients with solid tumors. HS-130 is an allogeneic (“off-the-shelf”) cell line engineered to express OX40 ligand fusion protein (OX40L-Fc). OX40 ligand is a key co-stimulator of T cells that augments antigen-specific CD8+ T cell responses.
COVID-19 Vaccine.
The company initiated a COVID-19 vaccine collaboration with the University of Miami in March 2020 using their gp96 platform which activates the human immune system to combat infectious diseases with the potential of generating long-term immune responses.
PTX-35.
PTX-35 is in Phase I clinical trial for patients with solid tumors. PTX-35 is a potential first-in-class T cell co-stimulator targeting TNFRSF25 (Death Receptor 3). Favorable safety profile was demonstrated in mice and non-human primates. PTX-35’s development plan focuses on cancer immunotherapy.
Heat Biologics stock.
Heat Biologics stock has been traded on the NASDAQ under ticker symbol HTBX since 24 July 2013.
Main people.
Heat Biologics' Chairman and CEO is Jeffrey Wolf, a serial Life Sciences entrepreneur who founded the company in 2008. 